Literature DB >> 8878441

Autoantibodies to nuclear envelope antigens in chronic fatigue syndrome.

K Konstantinov1, A von Mikecz, D Buchwald, J Jones, L Gerace, E M Tan.   

Abstract

We have identified and partially characterized the autoantibodies in sera of 60 patients with chronic fatigue syndrome. Approximately 52% of the sera were found to react with nuclear envelope antigens. The combination of nuclear rim staining observed in immunofluorescence microscopy and immunoblot analysis of highly purified nuclear envelope proteins provided initial characterization of these autoantibodies. Further characterization showed that some sera immunoprecipitated the in vitro transcription and translation product of a human cDNA clone encoding the nuclear envelope protein lamin B1. The autoantibodies were of the IgG isotype. The occurrence of autoantibodies to a conserved intracellular protein like lamin B1 provides new laboratory evidence for an autoimmune component in chronic fatigue syndrome.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8878441      PMCID: PMC507629          DOI: 10.1172/JCI118990

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  33 in total

1.  Autoantibodies to nuclear lamin C in the eosinophilia-myalgia syndrome associated with L-tryptophan ingestion.

Authors:  J Varga; G G Maul; S A Jimenez
Journal:  Arthritis Rheum       Date:  1992-01

2.  Circulating lymphokine levels in the chronic fatigue syndrome.

Authors:  S E Straus; J K Dale; J B Peter; C A Dinarello
Journal:  J Infect Dis       Date:  1989-12       Impact factor: 5.226

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group.

Authors:  K Fukuda; S E Straus; I Hickie; M C Sharpe; J G Dobbins; A Komaroff
Journal:  Ann Intern Med       Date:  1994-12-15       Impact factor: 25.391

5.  Antibodies to nuclear lamins in autoimmune liver disease.

Authors:  J Wesierska-Gadek; E Penner; E Hitchman; G Sauermann
Journal:  Clin Immunol Immunopathol       Date:  1988-10

6.  Autoantibodies to major and minor nuclear lamins are not restricted to autoimmune diseases.

Authors:  J L Senécal; Y Raymond
Journal:  Clin Immunol Immunopathol       Date:  1992-05

7.  Chronic fatigue: a peculiar evolution of eosinophilia myalgia syndrome following treatment with L-tryptophan in four Italian adolescents.

Authors:  R Priori; F Conti; F L Luan; C Arpino; G Valesini
Journal:  Eur J Pediatr       Date:  1994-05       Impact factor: 3.183

8.  In vitro posttranslational modification of lamin B cloned from a human T-cell line.

Authors:  K M Pollard; E K Chan; B J Grant; K F Sullivan; E M Tan; C A Glass
Journal:  Mol Cell Biol       Date:  1990-05       Impact factor: 4.272

9.  Integral membrane proteins associated with the nuclear lamina are novel autoimmune antigens of the nuclear envelope.

Authors:  K Konstantinov; R Foisner; D Byrd; F T Liu; W M Tsai; A Wiik; L Gerace
Journal:  Clin Immunol Immunopathol       Date:  1995-01

10.  Identification and characterization of autoantibodies against the nuclear envelope lamin B receptor from patients with primary biliary cirrhosis.

Authors:  J C Courvalin; K Lassoued; H J Worman; G Blobel
Journal:  J Exp Med       Date:  1990-09-01       Impact factor: 14.307

View more
  27 in total

Review 1.  Evidence for the presence of immune dysfunction in chronic fatigue syndrome.

Authors:  Benjamin H Natelson; Mohammad H Haghighi; Nicholas M Ponzio
Journal:  Clin Diagn Lab Immunol       Date:  2002-07

Review 2.  Primary biliary cirrhosis: what do autoantibodies tell us?

Authors:  Chao-Jun Hu; Feng-Chun Zhang; Yong-Zhe Li; Xuan Zhang
Journal:  World J Gastroenterol       Date:  2010-08-07       Impact factor: 5.742

Review 3.  The roles of the nuclear pore complex in cellular dysfunction, aging and disease.

Authors:  Stephen Sakuma; Maximiliano A D'Angelo
Journal:  Semin Cell Dev Biol       Date:  2017-05-12       Impact factor: 7.727

4.  Antinuclear autoantibodies (ANA) in Gulf War-related illness and chronic fatigue syndrome (CFS) patients.

Authors:  A Skowera; E Stewart; E T Davis; A J Cleare; C Unwin; L Hull; K Ismail; G Hossain; S C Wessely; M Peakman
Journal:  Clin Exp Immunol       Date:  2002-08       Impact factor: 4.330

Review 5.  Immunoglobulin-mediated neuro-cognitive impairment: new data and a comprehensive review.

Authors:  Assaf Menachem; Joab Chapman; Yael Deri; Chaim G Pick; Aviva Katzav
Journal:  Clin Rev Allergy Immunol       Date:  2013-10       Impact factor: 8.667

6.  The nuclear pore complex protein Tpr is a common autoantigen in sera that demonstrate nuclear envelope staining by indirect immunofluorescence.

Authors:  Y Ou; P Enarson; J B Rattner; S G Barr; M J Fritzler
Journal:  Clin Exp Immunol       Date:  2004-05       Impact factor: 4.330

7.  Plasmacytoid dendritic cells in the duodenum of individuals diagnosed with myalgic encephalomyelitis are uniquely immunoreactive to antibodies to human endogenous retroviral proteins.

Authors:  Kenny L De Meirleir; Svetlana F Khaiboullina; Marc Frémont; Jan Hulstaert; Albert A Rizvanov; András Palotás; Vincent C Lombardi
Journal:  In Vivo       Date:  2013 Mar-Apr       Impact factor: 2.155

8.  Clinical impact of B-cell depletion with the anti-CD20 antibody rituximab in chronic fatigue syndrome: a preliminary case series.

Authors:  Øystein Fluge; Olav Mella
Journal:  BMC Neurol       Date:  2009-07-01       Impact factor: 2.474

9.  High levels of type 2 cytokine-producing cells in chronic fatigue syndrome.

Authors:  A Skowera; A Cleare; D Blair; L Bevis; S C Wessely; M Peakman
Journal:  Clin Exp Immunol       Date:  2004-02       Impact factor: 4.330

Review 10.  Autoantigens of the nuclear pore complex.

Authors:  P Enarson; J B Rattner; Y Ou; K Miyachi; T Horigome; M J Fritzler
Journal:  J Mol Med (Berl)       Date:  2004-06-03       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.